Obesity – Page 9 – Talk Bio

Actionable Insights Powered by AI

Eli Lilly Rekindles Partnership with KeyBioscience to Bolster Obesity Drug Pipeline

7 months ago talkbio0Tagged Eli, Eli Lilly, KeyBioscience, Obesity, partnerships, Weight Loss

Eli Lilly, obesity drugs, KeyBioscience, partnerships, weight loss treatments

Lilly’s Obesity Drug Shortage Resolved, Novo’s Continues Amid Industry Efforts to Boost Manufacturing

7 months ago talkbio0Tagged Drug Shortage, Eli, Eli Lilly, Glucagon-Like Peptide 1, Mounjaro, Nordisk, Obesity, pharmaceutical manufacturing, Wegovy, Weight-Loss Agents, Zepbound

Eli Lilly, obesity drug shortage, Mounjaro, Zepbound, Novo Nordisk, Wegovy, GLP-1 drugs, pharmaceutical manufacturing, weight loss drugs.

NHS England to Roll Out Eli Lilly’s Obesity Drug Mounjaro in Phased Approach

7 months ago talkbio0Tagged Eli, Eli Lilly, England, Mounjaro, Nance-Horan syndrome, Obesity, Phase, rollout, Weight Loss

NHS England, Eli Lilly, Mounjaro, Obesity Drug, Phased Rollout, Weight Loss, Tirzepatide

Kailera Secures $400M Funding to Advance China-Developed Obesity and Diabetes Therapies

7 months ago talkbio0Tagged Diabetes, Kailera, Obesity

Kailera, obesity, diabetes, China-developed drugs, $400M funding, pharmaceuticals, biotech

Metsera and Amneal Collaborate on Next-Generation Obesity Medicines, with Leadership Transition at Metsera

7 months ago talkbio0Tagged Amneal, Leadership, Manufacture, Metsera, Obesity, Partnership, strategic collaboration, Transition Mutation

Metsera, Amneal, Obesity Drugs, Strategic Collaboration, Manufacturing Partnership, Leadership Transition

Metsera’s Long-Acting GLP-1 Drug Shows Promising 7.5% Weight Loss in 36 Days, Paving Way for Monthly Dosing

7 months ago talkbio0Tagged Clinical Trials, dosing, Glucagon-Like Peptide 1, long-acting drug, MET-097, Metsera, monthly, Monthly (qualifier value), Obesity

Metsera, GLP-1, obesity treatment, long-acting drug, weight loss, monthly dosing, MET-097, clinical trial results.

Eli Lilly and Novo Nordisk Support OAC’s Your Weight Matters Campaign Amidst Competitive Weight Loss Drug Market

7 months ago talkbio0Tagged care activity, Drug Industry, Eli, Eli Lilly, Glucagon-Like Peptide 1, Nordisk, OAC, Obesity, Weight-Loss Agents

Eli Lilly, Novo Nordisk, OAC, Your Weight Matters, weight loss drugs, GLP-1, obesity care, pharmaceutical industry

Novo Nordisk’s CB1 Drug Monlunabant Shows Weight Loss Potential, but Raises Efficacy and Safety Concerns

7 months ago talkbio0Tagged concerns, Effectiveness, monlunabant, neuropsychiatric side, Nordisk, Obesity, Receptor, Cannabinoid, CB1, Safety

Novo Nordisk, Monlunabant, CB1 receptor, obesity treatment, weight loss, efficacy, safety concerns, neuropsychiatric side effects

Pioneers in Obesity Treatment: Lasker Award Honors Scientists Behind GLP-1 Drugs

7 months ago talkbio0Tagged Glucagon-Like Peptide 1, Habener, Lasker Award, Lotte Bjerre Knudsen, Medical Research activity, Mojsov, Obesity

Lasker Award, GLP-1 drugs, obesity treatment, Joel Habener, Svetlana Mojsov, Lotte Bjerre Knudsen, medical research, pharmaceuticals.

Novo Nordisk’s GLP-1 Agonist Demonstrates Significant BMI Reduction in Children Aged 6-12 in Phase 3 Trial

8 months ago talkbio0Tagged agonists, Body mass index procedure, Glucagon-Like Peptide 1, liraglutide, Nordisk, Obesity, Pediatric brand name, Phase 3 trial, semaglutide

GLP-1 agonists, obesity, weight loss, liraglutide, semaglutide, pediatric obesity, BMI reduction, Novo Nordisk, Phase 3 trial.